Table 4 Local outcome and palliative effects
From: Helical TomoTherapy for locally advanced or recurrent breast cancer
All patients | Recurrence Treatment Group | Primary Treatment Group | |
|---|---|---|---|
End of HT | n = 26 | n = 12 | n = 14 |
Local partial remission | 6 (23%) | 4 (33%) | 2 (14%) |
Local complete remission | − | − | − |
Local stable disease | 20 (76%) | 6 (50%) | 12 (85%) |
Local progression | 2 (8%) | 2 (17%) | 0 |
Systemic progression | 4 (15%) | 2 (17%) | 2 (14%) |
Acute symptom relief | 7 (27%) | 5 (42%) | 2 (14%) |
6–8 weeks after HT | n = 23 | n = 12 | n = 11 |
Local partial remission | 8 (35%) | 6 (50%) | 2 (18%) |
Local complete remission | 4 (18%) | 4 (33%) | − |
Local stable disease | 7 (30%) | − | 7 (64%) |
Local progression | 1 (4%) | − | 1 (9%) |
Systemic progression | 3 (13% | 2 (17%) | 1 (9%) |
Lost to follow up | 2 | − | 2 |
Deceased | 1 | − | 1 |
3–4 months after HT | n = 17 | n = 8 | n = 9 |
Local partial remission | 2 (11%) | − | 2 (22%) |
Local complete remission | − | − | − |
Local stable disease | 7 (42%) | 3 (38%) | 4 (44%) |
Local progression | 3 (18%) | 1 (13%) | 2 (22%) |
Systemic progression | 5 (29%) | 4 (50%) | 1 (11%) |
Lost to follow up | 6 | 2 | 4 |
Deceased | 3 | 2 | 1 |